Company news
Lumosa Therapeutics Co Ltd (TPEX:6535) news
Lumosa Therapeutics Co Ltd news releases on 6ix. Latest, Feb 6, 2026: LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC…
Press releases & updates
LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE
February 6, 2026
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
October 28, 2025
Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic
August 9, 2022
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company
August 9, 2022
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards
August 9, 2022
Lumosa Therapeutics : Board of Directors approved the consolidated financial report for the second quarter of 2022
August 9, 2022
Lumosa Therapeutics : Board Approved the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic
May 31, 2022
Lumosa Therapeutics : Shareholders' Meeting approved to release the company's directors from non-competition restrictions
May 24, 2022
Lumosa Therapeutics : Important resolutions of LUMOSA's 2022 Annual Shareholders' Meeting
May 24, 2022
Lumosa Therapeutics : Board of Directors not to proceed with the private placement of ordinary shares approved by the 2021 annual general meeting of shareholders
April 22, 2022
LUMOSA Therapeutics : announces TFDA’s clearance of Phase 2 IND application for multiple-dose of LT3001 in patients with acute ischemic stroke.
March 24, 2022
Lumosa Therapeutics : Board of Directors approved the convening of the 2022 Annual shareholders' Meeting
March 4, 2022
Lumosa Therapeutics : Board of Directors approved to issue common shares via private placement.
March 4, 2022
Lumosa Therapeutics : Board of Directors approved the 2021 consolidated financial report
March 4, 2022
Lumosa Therapeutics : Receives the Results of LT1001 Phase 3 Trial Conducted by Chinese Partner, Jemincare
February 25, 2022
Lumosa Therapeutics : Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke.
February 9, 2022
Lumosa Therapeutics : Announces the Termination of “Comparative BA Study” for Naldebain, a New Long-Acting Analgesic Injection, in the US Due to Additional USFDA Requirements
January 26, 2022